Deubiquitylating Enzymes and DNA Damage Response Pathways

Cell Biochemistry and Biophysics

Volumn 67, Issue 1, 2013, Pages 25-43

  Jacq, Xavier ^a   Kemp, Mark ^a   Martin, Niall M B ^a   Jackson, Stephen P ^a,b  

^a Babraham Research Campus Babraham   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Checkpoint control; Deubiquitylating enzyme; DNA damage response; DNA repair; Drug discovery; DUB; Synthetic lethality; Ubiquitin

Indexed keywords

DEUBIQUITINASE; PROTEIN P53; UBIQUITIN THIOLESTERASE;

ARTICLE; DNA DAMAGE; DNA REPAIR; HUMAN; METABOLISM; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY;

DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; OXIDATIVE STRESS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84883458147     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9635-3     Document Type: Article

References (209)

1. Curtin, N. J. (2012). DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer, 12, 801-817.
2. Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: Making it safe to play with knives. Molecular Cell, 40, 179-204.
3. Jackson, S. P., & Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature, 461, 1071-1078.
4. Bradbury, J. M., & Jackson, S. P. (2003). The complex matter of DNA double-strand break detection. Biochemical Society Transactions, 31, 40-44.
5. Hartwell, L. H., & Kastan, M. B. (1994). Cell cycle control and cancer. Science, 266, 1821-1828.
6. Branzei, D., & Foiani, M. (2008). Regulation of DNA repair throughout the cell cycle. Nature Reviews Molecular Cell Biology, 9, 297-308.
7. Reinhardt, H. C., & Yaffe, M. B. (2009). Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Current Opinion in Cell Biology, 21, 245-255.
8. Bartek, J., & Lukas, J. (2007). DNA damage checkpoints: From initiation to recovery or adaptation. Current Opinion in Cell Biology, 19, 238-245.
9. Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. Science, 319, 1352-1355.
10. Kroemer, G., Mariño, G., & Levine, B. (2010). Autophagy and the integrated stress response. Molecular Cell, 40, 280-293.
11. Vousden, K. H., & Prives, C. (2009). Blinded by the light: The growing complexity of p53. Cell, 137, 413-431.
12. van Attikum, H., & Gasser, S. M. (2009). Crosstalk between histone modifications during the DNA damage response. Trends in Cell Biology, 19, 207-217.
13. Miller, K. M., & Jackson, S. P. (2012). Histone marks: Repairing DNA breaks within the context of chromatin. Biochemical Society Transactions, 40, 370-376.
14. Hoeijmakers, J. H. (2009). DNA damage, aging, and cancer. New England Journal of Medicine, 361, 1475-1485.
15. Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., et al. (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75, 1027-1038.
16. Lynch, H. T., & de la Chapelle, A. (1999). Genetic susceptibility to non-polyposis colorectal cancer. Journal of Medical Genetics, 36, 801-818.
17. Shiloh, Y. (1997). Ataxia-telangiectasia and the Nijmegen breakage syndrome: Related disorders but genes apart. Annual Review of Genetics, 31, 635-662.
18. Yuille, M. A., & Coignet, L. J. (1998). The ataxia telangiectasia gene in familial and sporadic cancer. Recent Results in Cancer Research, 154, 156-173.
19. McKinnon, P. J., & Caldecott, K. W. (2007). DNA strand break repair and human genetic disease. Annual Review of Genomics and Human Genetics, 8, 37-55.
20. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., et al. (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science, 266(5182), 120-122.
21. Wooster, R., Bignell, G., Lancaster, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789-792.
22. Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002). Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Journal of the National Cancer Institute, 94, 990-1000.
23. Berman, D. B., Costalas, J., Schultz, D. C., Grana, G., Daly, M., & Godwin, A. K. (1996). A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Research, 56, 3409-3414.
24. Friedenson, B. (2005). BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med, 7, 60.
25. D'Andrea, A. D., & Grompe, M. (2003). The Fanconi anaemia/BRCA pathway. Nature Reviews Cancer, 3, 23-34.
26. Hucl, T., & Gallmeier, E. (2011). DNA repair: Exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiological Research, 60, 453-465.
27. d'Adda di Fagagna, F., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., Von Zglinicki, T., et al. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
28. Jones, R. M., Mortusewicz, O., Afzal, I., Lorvellec, M., García, P., Helleday, T., & Petermann, E. (2012). Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene. doi: 10. 1038/onc. 2012. 387.
29. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-921.
30. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913-917.
31. Harper, J. W., & Elledge, S. J. (2007). The DNA damage response: Ten years after. Molecular Cell, 28, 739-745.
32. Polo, S. E., & Jackson, S. P. (2011). Dynamics of DNA damage response proteins at DNA breaks: A focus on protein modifications. Genes & Development, 25, 409-433.
33. Huen, M. S., & Chen, J. (2008). The DNA damage response pathways: At the crossroad of protein modifications. Cell Research, 18, 8-16.
34. Alpi, A. F., & Patel, K. J. (2009). Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amsterdam), 8, 430-435.
35. Panier, S., & Durocher, D. (2009). Regulatory ubiquitylation in response to DNA double-strand breaks. DNA Repair (Amsterdam), 8, 436-443.
36. Messick, T. E., & Greenberg, R. A. (2009). The ubiquitin landscape at DNA double-strand breaks. Journal of Cell Biology, 187, 319-326.
37. Fraile, J. M., Quesada, V., Rodríguez, D., Freije, J. M., & López-Otín, C. (2012). Deubiquitinases in cancer: New functions and therapeutic options. Oncogene, 31, 2373-2388.
38. Jackson, S. P., & Durocher, D. (2013). Regulation of DNA responses by ubiquitin and SUMO. Molecular Cell (in press).
39. Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. Annual Review of Biochemistry, 67, 425-479.
40. Wilkinson, K. D. (2000). Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Seminars in Cell & Developmental Biology, 11, 141-148.
41. Varshavsky, A. (2012). The ubiquitin system, an immense realm. Annual Review of Biochemistry, 81, 167-176.
42. Hicke, L. (2001). Protein regulation by monoubiquitin. Nature Reviews Molecular Cell Biology, 2, 195-201.
43. Ikeda, F., & Dikic, I. (2008). Atypical ubiquitin chains: New molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Reports, 9, 536-542.
44. Iwai, K. (2012). Diverse ubiquitin signaling in NF-κB activation. Trends in Cell Biology, 22, 355-364.
45. Komander, D., & Rape, M. (2012). The ubiquitin code. Annual Review of Biochemistry, 81, 203-229.
46. Hay, R. T. (2007). SUMO-specific proteases: A twist in the tail. Trends in Cell Biology, 17, 370-376.
47. Hochstrasser, M. (2009). Origin and function of ubiquitin-like proteins. Nature, 2009(458), 422-429.
48. van der Veen, A. G., & Ploegh, H. L. (2012). Ubiquitin-like proteins. Annual Review of Biochemistry, 81, 323-357.
49. Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009). Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annual Review of Biochemistry, 78, 363-397.
50. Reyes-Turcu, F. E., & Wilkinson, K. D. (2009). Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chemical Reviews, 109, 1495-1508.
51. Sacco, J. J., Coulson, J. M., Clague, M. J., & Urbé, S. (2010). Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life, 62, 140-157.
52. Zhang, D., & Zhang, D. E. (2011). Interferon-stimulated gene 15 and the protein ISGylation system. Journal of Interferon and Cytokine Research, 31, 119-130.
53. Dou, H., Huang, C., Singh, M., Carpenter, P. B., & Yeh, E. T. (2010). Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Molecular Cell, 39, 333-345.
54. Komander, D., Clague, M. J., & Urbé, S. (2009). Breaking the chains: Structure and function of the deubiquitinases. Nature Reviews Molecular Cell Biology, 10, 550-563.
55. Lindner, H. A. (2007). Deubiquitination in virus infection. Virology, 362, 245-256.
56. Sun, S. C. (2008). Deubiquitylation and regulation of the immune response. Nature Reviews Immunology, 8(7), 501-511.
57. Hussain, S., Zhang, Y., & Galardy, P. J. (2009). DUBs and cancer: The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle, 8, 1688-1697.
58. Ramakrishna, S., Suresh, B., & Baek, K. H. (2011). The role of deubiquitinating enzymes in apoptosis. Cellular and Molecular Life Sciences, 68, 15-26.
59. Hibbert, R. G., Mattiroli, F., & Sixma, T. K. (2009). Structural aspects of multi-domain RING/Ubox E3 ligases in DNA repair. DNA Repair (Amsterdam), 8, 525-535.
60. Hofmann, K. (2009). Ubiquitin-binding domains and their role in the DNA damage response. DNA Repair (Amsterdam), 8, 544-556.
61. Al-Hakim, A., Escribano-Diaz, C., Landry, M. C., O'Donnell, L., Panier, S., Szilard, R. K., et al. (2010). The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amsterdam), 9, 1229-1240.
62. Nijman, S. M., Huang, T. T., Dirac, A. M., Brummelkamp, T. R., Kerkhoven, R. M., D'Andrea, A. D., et al. (2005). The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Molecular Cell, 17, 331-339.
63. Huang, T. T., Nijman, S. M., Mirchandani, K. D., Galardy, P. J., Cohn, M. A., Haas, W., et al. (2006). Regulation of monoubiquitinated PCNA by DUB autocleavage. Nature Cell Biology, 8, 339-347.
64. Taniguchi, T., Garcia-Higuera, I., Andreassen, P. R., Gregory, R. C., Grompe, M., & D'Andrea, A. D. (2002). S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood, 100, 2414-2420.
65. Wang, X., Andreassen, P. R., & D'Andrea, A. D. (2004). Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Molecular and Cellular Biology, 24, 5850-5862.
66. Montes de Oca, R., Andreassen, P. R., Margossian, S. P., Gregory, R. C., Taniguchi, T., Wang, X., et al. (2005). Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood, 105, 1003-1009.
67. Cohn, M. A., Kowal, P., Yang, K., Haas, W., Huang, T. T., Gygi, S. P., et al. (2007). A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Molecular Cell, 28, 786-797.
68. Lee, S. W., Lee, M. H., Park, J. H., Kang, S. H., Yoo, H. M., Ka, S. H., Oh, Y. M., Jeon, Y. J., & Chung, C. H. (2012, October 23). SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO Journal.
69. Sikdar, N., Banerjee, S., Lee, K. Y., Wincovitch, S., Pak, E., Nakanishi, K., et al. (2009). DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. Cell Cycle, 8, 3199-3207.
70. Kim, J. M., Parmar, K., Huang, M., Weinstock, D. M., Ruit, C. A., Kutok, J. L., et al. (2009). Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Developmental Cell, 16, 314-320.
71. Oestergaard, V. H., Langevin, F., Kuiken, H. J., Pace, P., Niedzwiedz, W., Simpson, L. J., et al. (2007). Deubiquitylation of FANCD2 is required for DNA crosslink repair. Molecular Cell, 28, 798-809.
72. Murai, J., Yang, K., Dejsuphong, D., Hirota, K., Takeda, S., & D'Andrea, A. D. (2011). The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Molecular and Cellular Biology, 31, 2462-2469.
73. Guervilly, J. H., Renaud, E., Takata, M., & Rosselli, F. (2011). USP1 deubiquitinase maintains phosphorylated CHK1 by limiting its DDB1-dependent degradation. Human Molecular Genetics, 20, 2171-2181.
74. Jones, M. J., Colnaghi, L., & Huang, T. T. (2011). Dysregulation of DNA polymerase κ recruitment to replication forks results in genomic instability. EMBO Journal, 31, 908-918.
75. Ogi, T., Limsirichaikul, S., Overmeer, R. M., Volker, M., Takenaka, K., Cloney, R., et al. (2010). Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Molecular Cell, 37, 714-727.
76. Cotto-Rios, X. M., Jones, M. J., Busino, L., Pagano, M., & Huang, T. T. (2011). APC/CCdh1-dependent proteolysis of USP1 regulates the response to UV-mediated DNA damage. Journal of Cell Biology, 194, 177-186.
77. Williams, S. A., Maecker, H. L., French, D. M., Liu, J., Gregg, A., Silverstein, L. B., et al. (2011). USP1 deubiquitylates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell, 146, 918-930.
78. Lasorella, A., Uo, T., & Iavarone, A. (2001). Id proteins at the cross-road of development and cancer. Oncogene, 20, 8326-8333.
79. Lasorella, A., Stegmuller, J., Guardavaccaro, D., Liu, G., Carro, M. S., Rothschild, G., et al. (2006). Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature, 442, 471-474.
80. Priolo, C., Tang, D., Brahamandan, M., Benassi, B., Sicinska, E., Ogino, S., et al. (2006). The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Research, 66, 8625-8632.
81. Stevenson, L. F., Sparks, A., Allende-Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO Journal, 26, 976-986.
82. Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010). MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene, 29, 432-441.
83. Nicassio, F., Corrado, N., Vissers, J. H., Areces, L. B., Bergink, S., Marteijn, J. A., et al. (2007). Human USP3 is a chromatin modifier required for S phase progression and genome stability. Current Biology, 17, 1972-1977.
84. Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D. H., Pepperkok, R., et al. (2009). RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell, 136, 435-446.
85. Buus, R., Faronato, M., Hammond, D. E., Urbé, S., & Clague, M. J. (2009). Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells. Current Biology, 19, 1463-1466.
86. Zhang, X., Berger, F. G., Yang, J., & Lu, X. (2011). USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO Journal, 30, 2177-2189.
87. Liang, L., Fan, Y., Cheng, J., Cheng, D., Zhao, Y., Cao, B., et al. (2012). TAK1 ubiquitylation regulates doxorubicin-induced NF-κB activation. Cellular Signalling, 25, 247-254.
88. Zhou, F., Zhang, X., van Dam, H., Ten Dijke, P., Huang, H., & Zhang, L. (2012). Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. Journal of Biological Chemistry, 287, 11002-11010.
89. Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., et al. (2012). USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nature Cell Biology, 14, 717-726.
90. Aggarwal, K., & Massagué, J. (2012). Ubiquitin removal in the TGF-β pathway. Nature Cell Biology, 14, 656-657.
91. Xiao, N., Li, H., Luo, J., Wang, R., Chen, H., Chen, J., et al. (2012). Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitylation and inhibits TNFα-induced cancer cell migration. Biochemistry Journal, 441, 979-986.
92. Uras, I. Z., List, T., Nijman, S. M. (2012). Ubiquitin-specific protease 4 inhibits mono-ubiquitylation of the master growth factor signaling kinase PDK1. PLoS One, 7, 31003.
93. Zhao, B., Schlesiger, C., Masucci, M. G., & Lindsten, K. (2009). The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. Journal of Cellular and Molecular Medicine, 8B, 1886-1895.
94. Dayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2009). Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. Journal of Biological Chemistry, 284, 5030-5041.
95. Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F., Ovaa, H., Abraham, T. E., et al. (2005). Loss of HAUSP-mediated deubiquitylation contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Molecular Cell, 18, 565-576.
96. Faustrup, H., Bekker-Jensen, S., Bartek, J., Lukas, J., & Mailand, N. (2009). USP7 counteracts SCFbetaTrCP- but not APCCdh1-mediated proteolysis of Claspin. Journal of Cell Biology, 18, 13-19.
97. Khoronenkova, S. V., Dianova, I. I., Ternette, N., Kessler, B. M., Parsons, J. L., & Dianov, G. L. (2012). ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Molecular Cell, 45, 801-813.
98. van der Horst, A., de Vries-Smits, A. M., Brenkman, A. B., van Triest, M. H., van den Broek, N., Colland, F., et al. (2006). FOXO4 transcriptional activity is regulated by monoubiquitylation and USP7/HAUSP. Nature Cell Biology, 10, 1064-1073.
99. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646-674.
100. Khoronenkova, S. V., Dianova, I. I., Parsons, J. L., & Dianov, G. L. (2011). USP7/HAUSP stimulates repair of oxidative DNA lesions. Nucleic Acids Research, 7, 2604-2609.
101. Hanawalt, P. C., & Spivak, G. (2008). Transcription-coupled DNA repair: Two decades of progress and surprises. Nature Reviews Molecular Cell Biology, 12, 958-970.
102. Schwertman, P., Lagarou, A., Dekkers, D. H., Raams, A., van der Hoek, A. C., Laffeber, C., et al. (2012). UV-sensitive syndrome protein UVSSA recruits USP7 to regulate transcription-coupled repair. Nature Genetics, 5, 598-602.
103. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., et al. (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature, 416, 648-653.
104. Youle, R. J., & Strasser, A. (2008). The BCL-2 protein family: Opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 9, 47-59.
105. Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., et al. (2010). Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 463, 103-107.
106. Trivigno, D., Essmann, F., Huber, S. M., & Rudner, J. (2012). Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia, 14, 893-904.
107. Harris, D. R., Mims, A., & Bunz, F. (2012). Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil. Cancer Biology & Therapy, 13, 1319-1324.
108. Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010). USP10 regulates p53 localization and stability by deubiquitinating p53. Cell, 140, 384-396.
109. Liu, J., Xia, H., Kim, M., Xu, L., Li, Y., Zhang, L., et al. (2011). Beclin1 controls the levels of p53 by regulating the deubiquitylation activity of USP10 and USP13. Cell, 147, 223-234.
110. Maertens, G. N., El Messaoudi-Aubert, S., Elderkin, S., Hiom, K., & Peters, G. (2010). Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. EMBO Journal, 29, 2553-2565.
111. Wiltshire, T. D., Lovejoy, C. A., Wang, T., Xia, F., O'Connor, M. J., & Cortez, D. (2010). Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. The Journal of Biological Chemistry, 285, 14565-14571.
112. Patel, K. J., Yu, V. P., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., et al. (1998). Involvement of Brca2 in DNA repair. Molecular Cell, 1, 347-357.
113. Tutt, A., Gabriel, A., Bertwistle, D., Connor, F., Paterson, H., Peacock, J., et al. (1999). Absence of BRCA2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Current Biology, 9, 1107-1110.
114. Yu, V. P., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L. A., van Gool, A. J., et al. (2000). Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes & Development, 14, 1400-1406.
115. Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001). BRCA2 is required for homology-directed repair of chromosomal breaks. Molecular Cell, 7, 263-272.
116. Tutt, A., Bertwistle, D., Valentine, J., Gabriel, A., Swift, S., Ross, G., et al. (2001). Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO Journal, 20, 4704-4716.
117. Schoenfeld, A. R., Apgar, S., Dolios, G., Wang, R., & Aaronson, S. A. (2004). BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Molecular and Cellular Biology, 24, 7444-7455.
118. Joo, H. Y., Zhai, L., Yang, C., Nie, S., Erdjument-Bromage, H., Tempst, P., et al. (2007). Regulation of cell cycle progression and gene expression by H2A deubiquitylation. Nature, 449, 1068-1072.
119. Shanbhag, N. M., Rafalska-Metcalf, I. U., Balane-Bolivar, C., Janicki, S. M., & Greenberg, R. A. (2010). ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell, 141, 970-981.
120. Mattiroli, F., Vissers, J. H., van Dijk, W. J., Ikpa, P., Citterio, E., Vermeulen, W., et al. (2012). RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell, 150, 1182-1195.
121. Zhang, L., Lubin, A., Chen, H., Sun, Z., & Gong, F. (2012). The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2 stability. Cell Cycle, 1, 23.
122. Bakkenist, C. J., & Kastan, M. B. (2004). Initiating cellular stress responses. Cell, 118, 9-17.
123. Wang, B., Matsuoka, S., Carpenter, P. B., & Elledge, S. J. (2002). 53BP1, a mediator of the DNA damage checkpoint. Science, 298, 1435-1438.
124. Ward, I. M., Minn, K., van Deursen, J., & Chen, J. (2003). p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Molecular and Cellular Biology, 7, 2556-2563.
125. Zhang, D., Zaugg, K., Mak, T. W., & Elledge, S. J. (2006). A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell, 126, 529-542.
126. Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., et al. (2007). The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biology, 7, 765-774.
127. Jiang, M. R., Li, Y. C., Yang, Y., & Wu, J. R. (2003). C-Myc degradation induced by DNA damage results in apoptosis of CHO cells. Oncogene, 2, 2325-2359.
128. Herbst, A., Hemann, M. T., Tworkowski, K. A., Salghetti, S. E., Lowe, S. W., & Tansey, W. P. (2005). A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Reports, 2, 177-183.
129. Popov, N., Herold, S., Llamazares, M., Schülein, C., & Eilers, M. (2007). Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle, 6, 2327-2331.
130. Liu, J., Chung, H. J., Vogt, M., Jin, Y., Malide, D., He, L., et al. (2011). JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO Journal, 30, 846-858.
131. Musacchio, A., & Salmon, E. D. (2007). The spindle-assembly checkpoint in space and time. Nature Reviews Molecular Cell Biology, 8, 379-393.
132. Stegmeier, F., Rape, M., Draviam, V. M., Nalepa, G., Sowa, M. E., Ang, X. L., et al. (2007). Anaphase initiation is regulated by antagonistic ubiquitylation and deubiquitylation activities. Nature, 446, 876-881.
133. Song, L., & Rape, M. (2010). Regulated degradation of spindle assembly factors by the anaphase-promoting complex. Molecular Cell, 38, 369-382.
134. Zhang, Y., van Deursen, J., & Galardy, P. J. (2011). Overexpression of ubiquitin specific protease 44 (USP44) induces chromosomal instability and is frequently observed in human T-cell leukemia. PLoS ONE, 6, e23389.
135. Zhang, Y., Foreman, O., Wigle, D. A., Kosari, F., Vasmatzis, G., Salisbury, J. L., et al. (2012). USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis. The Journal of Clinical Investigation, 122, 4362-4374.
136. Lindahl, T. (1993). Instability and decay of the primary structure of DNA. Nature, 362, 709-715.
137. Dianov, G. L., & Parsons, J. L. (2007). Co-ordination of DNA single strand break repair. DNA Repair (Amsterdam), 6, 454-460.
138. Parsons, J. L., Dianova, I. I., Khoronenkova, S. V., Edelmann, M. J., Kessler, B. M., & Dianov, G. L. (2011). USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase beta. Molecular Cell, 41, 609-615.
139. Peschiaroli, A., Skaar, J. R., Pagano, M., & Melino, G. (2010). The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene, 29, 1384-1393.
140. Xiang, T., Li, L., Yin, X., Yuan, C., Tan, C., Su, X., et al. (2012). The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS ONE, 7, e29783.
141. Li, L., Tao, Q., Jin, H., van Hasselt, A., Poon, F. F., Wang, X., et al. (2010). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clinical Cancer Research, 16, 2949-2958.
142. Ummanni, R., Jost, E., Braig, M., Lohmann, F., Mundt, F., Barett, C., et al. (2011). Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Molecular Cancer, 10, 129.
143. Hussain, S., Foreman, O., Perkins, S. L., Witzig, T. E., Miles, R. R., van Deursen, J., et al. (2010). The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia, 24, 1641-1655.
144. Zhong, J., Zhao, M., Ma, Y., Luo, Q., Liu, J., Wang, J., et al. (2012). UCHL1 acts as a colorectal cancer oncogene via activation of the β-catenin/TCF pathway through its deubiquitinating activity. International Journal of Molecular Medicine, 30, 430-436.
145. Dong, Y., Hakimi, M. A., Chen, X., Kumaraswamy, E., Cooch, N. S., Godwin, A. K., et al. (2003). Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Molecular Cell, 12, 1087-1099.
146. Chen, X., Arciero, C. A., Wang, C., Broccoli, D., & Godwin, A. K. (2006). BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Research, 66, 5039-5046.
147. Sobhian, B., Shao, G., Lilli, D. R., Culhane, A. C., Moreau, L. A., Xia, B., et al. (2007). RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science, 316, 1198-1202.
148. Shao, G., Patterson-Fortin, J., Messick, T. E., Feng, D., Shanbhag, N., Wang, Y., et al. (2009). MERIT40 controls BRCA1-RAP80 complex integrity and recruitment to DNA double-strand breaks. Genes & Development, 23, 740-754.
149. Shao, G., Lilli, D. R., Patterson-Fortin, J., Coleman, K. A., Morrissey, D. E., & Greenberg, R. A. (2009). The RAP80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitylation events at DNA double strand breaks. Proceedings of the National Academy of Sciences of the United States of America, 106, 3166-3171.
150. Coleman, K. A., & Greenberg, R. A. (2011). The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. Journal of Biological Chemistry, 286, 13669-13680.
151. Fisch, P., Forster, A., Sherrington, P. D., Dyer, M. J., & Rabbitts, T. H. (1993). The chromosomal translocation t(X;14)(q28;q11) in T-cell pro-lymphocytic leukaemia breaks within one gene and activates another. Oncogene, 8, 3271-3276.
152. Zhu, P., Zhou, W., Wang, J., Puc, J., Ohgi, K. A., Erdjument-Bromage, H., et al. (2007). A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Molecular Cell, 27, 609-621.
153. Jiang, X. X., Nguyen, Q., Chou, Y., Wang, T., Nandakumar, V., Yates, P., et al. (2011). Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity, 35, 883-896.
154. Nijnik, A., Clare, S., Hale, C., Raisen, C., McIntyre, R. E., Yusa, K., et al. (2012). The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiation. Blood, 119, 1370-1379.
155. Panier, S., Ichijima, Y., Fradet-Turcotte, A., Leung, C. C., Kaustov, L., Arrowsmith, C. H., et al. (2012). Tandem protein interaction modules organize the ubiquitin-dependent response to DNA double-strand breaks. Molecular Cell, 47, 383-395.
156. Bekker-Jensen, S., & Mailand, N. (2011). The ubiquitin- and SUMO-dependent signaling response to DNA double-strand breaks. FEBS Letters, 585, 2914-2919.
157. Butler, L. R., Densham, R. M., Jia, J., Garvin, A. J., Stone, H. R., Shah, V., et al. (2012). The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. EMBO Journal, 31, 3918-3934.
158. Morris, J. R. (2012). Attenuation of the ubiquitin conjugate DNA damage signal by the proteasomal DUB POH1. Cell Cycle, 11, 22.
159. Galanty, Y., Belotserkovskaya, R., Coates, J., & Jackson, S. P. (2012). RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair. Genes & Development, 26, 1179-1195.
160. Nakada, S., Tai, I., Panier, S., Al-Hakim, A., Iemura, S., Juang, Y. C., et al. (2010). Non-canonical inhibition of DNA damage-dependent ubiquitylation by OTUB1. Nature, 466, 941-946.
161. Juang, Y. C., Landry, M. C., Sanches, M., Vittal, V., Leung, C. C., Ceccarelli, D. F., et al. (2012). OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Molecular Cell, 45, 384-397.
162. Sato, Y., Yamagata, A., Goto-Ito, S., Kubota, K., Miyamoto, R., Nakada, S., et al. (2012). Molecular basis of Lys-63-linked polyubiquitylation inhibition by the interaction between human deubiquitinating enzyme OTUB1 and ubiquitin-conjugating enzyme UBC13. Journal of Biological Chemistry, 287, 25860-25868.
163. Wiener, R., Zhang, X., Wang, T., & Wolberger, C. (2012). The mechanism of OTUB1-mediated inhibition of ubiquitylation. Nature, 483, 618-622.
164. Sun, X. X., Challagundla, K. B., & Dai, M. S. (2011). Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO Journal, 31, 576-592.
165. Yang, Y., Fu, W., Chen, J., Olashaw, N., Zhang, X., Nicosia, S. V., et al. (2007). SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nature Cell Biology, 9, 1253-1262.
166. Yates, K. E., Korbel, G. A., Shtutman, M., Roninson, I. B., & DiMaio, D. (2008). Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell, 7, 609-621.
167. Bawa-Khalfe, T., Cheng, J., Lin, S. H., Ittmann, M. M., & Yeh, E. T. (2010). SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. Journal of Biological Chemistry, 285, 25859-25866.
168. Li, X., Lee, Y. K., Jeng, J. C., Yen, Y., Schultz, D. C., Shih, H. M., et al. (2007). Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. Journal of Biological Chemistry, 282, 36177-36189.
169. Lee, M. H., Mabb, A. M., Gill, G. B., Yeh, E. T., & Miyamoto, S. (2011). NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Molecular Cell, 43, 180-191.
170. Moumen, A., Masterson, P., O'Connor, M. J., & Jackson, S. P. (2005). hnRNP K: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell, 123, 1065-1078.
171. Jiang, M., Chiu, S. Y., & Hsu, W. (2011). SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death and Differentiation, 18, 1005-1015.
172. Dou, H., Huang, C., van Nguyen, T., Lu, L. S., & Yeh, E. T. (2011). SUMOylation and de-SUMOylation in response to DNA damage. FEBS Letters, 585, 2891-2896.
173. Cheng, Z., Ke, Y., Ding, X., Wang, F., Wang, H., Wang, W., et al. (2008). Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response. Oncogene, 27, 931-941.
174. Isaacson, M. K., & Ploegh, H. L. (2009). Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host & Microbe, 5, 559-570.
175. Whitehurst, C. B., Vaziri, C., Shackelford, J., & Pagano, J. S. (2012). Epstein-Barr virus BPLF1 deubiquitylates PCNA and attenuates polymerase η recruitment to DNA damage sites. Journal of Virology, 86, 8097-8106.
176. Adams, J. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417-421.
177. Vassilev, L. T. (2007). MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine, 13, 23-31.
178. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 458, 732-736.
179. Ceccarelli, D. F., Tang, X., Pelletier, B., Orlicky, S., Xie, W., Plantevin, V., et al. (2011). An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell, 145, 1075-1087.
180. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011). Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Reviews Drug Discovery, 10, 29-46.
181. Nicholson, B., Marblestone, J. G., Butt, T. R., & Mattern, M. R. (2007). Deubiquitinating enzymes as novel anticancer targets. Future Oncology, 3, 191-199.
182. Cohen, P., & Tcherpakov, M. (2010). Will the ubiquitin system furnish as many drug targets as protein kinases? Cell, 143, 686-693.
183. Edelmann, M. J., Nicholson, B., & Kessler, B. M. (2011). Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Reviews in Molecular Medicine, 13, e35.
184. Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011). Searching for synthetic lethality in cancer. Current Opinion in Genetics & Development, 21, 34-41.
185. Yap, T. A., & Workman, P. (2012). Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annual Review of Pharmacology and Toxicology, 52, 549-573.
186. Morandell, S., & Yaffe, M. B. (2012). Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. Progress in Molecular Biology and Translational Science, 110, 289-314.
187. Bouwman, P., & Jonkers, J. (2012). The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Reviews Cancer, 12, 587-598.
188. Chen, J., Dexheimer, T. S., Ai, Y., Liang, Q., Villamil, M. A., Inglese, J., et al. (2011). Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chemistry & Biology, 18, 1390-1400.
189. Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., et al. (2009). Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Molecular Cancer Therapeutics, 8, 2286-2295.
190. Colombo, M., Vallese, S., Peretto, I., Jacq, X., Rain, J. C., Colland, F., et al. (2010). Synthesis and biological evaluation of 9-oxo-9H-indeno[1, 2-b]pyrazine-2, 3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. Chem Med Chem, 5, 552-558.
191. Fernández-Montalván, A., Bouwmeester, T., Joberty, G., Mader, R., Mahnke, M., Pierrat, B., et al. (2007). Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization. FEBS Journal, 274, 4256-4270.
192. Wrigley, J. D., Eckersley, K., Hardern, I. M., Millard, L., Walters, M., Peters, S. W., et al. (2011). Enzymatic characterisation of USP7 deubiquitinating activity and inhibition. Cell Biochemistry and Biophysics, 60, 99-111.
193. Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G., Zhou, B., Carrasco, R., et al. (2012). A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell, 22, 345-358.
194. Weinstock, J., Wu, J., Cao, P., Kingsbury, W., McDermott, J., Kodrasov, M., et al. (2012). Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47. ACS Medicinal Chemistry Letters, 3, 789-792.
195. Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., et al. (2012). Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chemistry & Biology, 19, 467-477.
196. Zhang, Y., Zhou, L., Rouge, L., Phillips, A. H., Lam, C., Liu, P., et al. (2013). Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nature Chemical Biology, 9, 51-58.
197. Liu, Y., Lashuel, H. A., Choi, S., Xing, X., Case, A., Ni, J., et al. (2003). Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chemistry & Biology, 10, 837-846.
198. Li, Z., Melandri, F., Berdo, I., Jansen, M., Hunter, L., Wright, S., et al. (2004). Delta12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochemical and Biophysical Research Communications, 319, 1171-1180.
199. Verbitski, S. M., Mullally, J. E., Fitzpatrick, F. A., & Ireland, C. M. (2004). Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity. Journal of Medicinal Chemistry, 47, 2062-2070.
200. Hirayama, K., Aoki, S., Nishikawa, K., Matsumoto, T., & Wada, K. (2007). Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. Bioorganic & Medicinal Chemistry, 15, 6810-6818.
201. Mitsui, T., Hirayama, K., Aoki, S., Nishikawa, K., Uchida, K., Matsumoto, T., et al. (2010). Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening. Neurochemistry International, 56, 679-686.
202. Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Talpaz, M., & Donato, N. J. (2010). Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Research, 70, 9265-9276.
203. Altun, M., Kramer, H. B., Willems, L. I., McDermott, J. L., Leach, C. A., Goldenberg, S. J., et al. (2011). Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chemistry & Biology, 18, 1401-1412.
204. Issaenko, O. A., & Amerik, A. Y. (2012). Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle, 11, 1804-1817.
205. Park, J. Y., Kim, J. H., Kim, Y. M., Jeong, H. J., Kim, D. W., Park, K. H., et al. (2012). Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorganic & Medicinal Chemistry, 20, 5928-5935.
206. Davies, C. W., Chaney, J., Korbel, G., Ringe, D., Petsko, G. A., Ploegh, H., et al. (2012). The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorganic & Medicinal Chemistry Letters, 22, 3900-3940.
207. Albrow, V. E., Ponder, E. L., Fasci, D., Békés, M., Deu, E., Salvesen, G. S., et al. (2011). Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. Chemistry & Biology, 18, 722-732.
208. Uno, M., Koma, Y., Ban, H. S., & Nakamura, H. (2012). Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 22, 5169-5173.
209. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New England Journal of Medicine, 361, 123-134.